83.3 F
New York
HomeMedicine

Medicine

Cryo Sculpting Lab Announces Revolutionary Franchise Opportunity in Non-Invasive Body Contouring

The CSL franchise requires a minimal initial investment, starting at just $49,750, which includes a state-of-the-art cryo sculpting machine and an $18,000 franchise fee. Entrepreneurs can begin operations in a compact 150-square-foot space, such as a private suite or shared salon, eliminating the need...

KCU’s Dr. Rex Archer receives prestigious F. Douglas Scutchfield Leadership Award for work in public health

KANSAS CITY, Mo., June 21, 2024 /PRNewswire/ -- The Public Health Accreditation Board (PHAB) honored Rex Archer, MD, MPH, Kansas City University (KCU) professor and director of population and public health, with their esteemed F. Douglas Scutchfield Leadership Award in recognition of his outstanding...

Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions

Data highlight potential of first-in-class CD8 Treg modulator Phase 1 clinical trial underway to evaluate MTX-101 in healthy adults and patients with celiac disease or type 1 diabetes SEATTLE, June 21, 2024 /PRNewswire/ -- Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development...

Leading Molecular Diagnostics Company BillionToOne Raises $130 Million in Oversubscribed Series D Funding Over $1B+ Valuation

The financing will further scale BillionToOne's prenatal screening and oncology diagnostics businesses MENLO PARK, Calif., June 21, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company, announced today that it has raised $130 million in an oversubscribed, upsized Series D round. The financing was...

FDA Roundup: June 21, 2024

SILVER SPRING, Md., June 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published final guidance titled Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection....

Use of Tirzepatide Shown to Improve Sleep Apnea and Cardiovascular Outcomes

SURMOUNT-OSA Study Highlights Potential Dual-Action Benefits of Novel Therapy for Obesity ORLANDO, Fla., June 21, 2024 /PRNewswire/ -- Today, findings from the SURMOUNT-OSA, a study of tirzepatide in patients with obstructive sleep apnea (OSA) and obesity, were announced, revealing significant improvements in both sleep apnea...